807-38-5

Basic information

• Product Name: 6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
• Synonyms: 6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione;6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione;6α-Fluorotriamcinolone;(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-11,16,17-trihydroxy-17-(2-hydroxyethanoyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one;(6S,8S,9R,10S,11S,13S,14S,16R,17S)-6,9-difluoro-17-glycoloyl-11,16,17-trihydroxy-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• CAS NO: 807-38-5
• Molecular Formula: C₂₁H₂₆F₂O₆
• Molecular Weight: 412.4243464
• EINECS: 212-362-9
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Steroids
• Mol File: 807-38-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 266-268 °C(Solv: ethyl acetate (141-78-6); methanol (67-56-1))
• Boiling Point: 589°C at 760 mmHg
• Flash Point: 310°C
• Appearance: /
• Density: 1.45g/cm³
• Vapor Pressure: 2.51E-16mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
• PKA: 11.42±0.70(Predicted)
• CAS DataBase Reference: 6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione(807-38-5)
• EPA Substance Registry System: 6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione(807-38-5)

Safety Data

• Hazardous Substances Data: 807-38-5(Hazardous Substances Data)

Usage

Uses

Fluocinolone, is a medication, used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin condition. It is also a derivative of Fluocinolone Acetonide (F455800).

InChI:InChI=1/C21H26F2O6/c1-18-4-3-10(25)5-13(18)14(22)6-12-11-7-15(26)21(29,17(28)9-24)19(11,2)8-16(27)20(12,18)23/h3-5,11-12,14-16,24,26-27,29H,6-9H2,1-2H3/t11-,12-,14-,15+,16-,18-,19-,20-,21-/m0/s1

Upstream product

• 67-73-2 fluocinolone Acetonide 

Downstream Products

• 1159113-31-1 (4aS,4bR,5S,6aS,6bS,8R,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8-(4-{[3-(methylthio)phenyl]thio}phenyl)-4a,4b,5,6,6a,6-b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho-[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one 
• 1159113-33-3 (4aS,4bR,5S,6aS,6bS,8R,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-8-(4-{[(4-hydroxyphenyl)thio]methyl}phenyl)-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one 
• 1159113-35-5 (4aS,4bR,5S,6aS,6bS,8R,9aR,10aS,10bS,12S)-8-(4-{[(3-chloro-4-hydroxyphenyl)thio]methyl}phenyl)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one 
• 1337894-72-0 C₃₃H₃₉F₂NO₇ 
• 1337894-73-1 C₃₅H₃₆F₂O₇ 
• 1337894-74-2 C₃₂H₃₂F₂N₂O₈ 
• 1337894-76-4 C₃₅H₃₆F₂O₆S 
• 1337894-77-5 C₃₅H₃₆F₂O₇S 
• 1337894-70-8 C₃₄H₃₄F₂O₇ 
• 1159113-30-0 (4aS,4bR,5S,6aS,6bS,8R,9aR,10aS,10bS,12S)-8-(4-benzylphenyl)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one 
• 1337894-75-3 C₃₅H₃₆F₂O₆S 
• 1337894-71-9 C₃₄H₃₄F₂O₆ 
• 1365915-07-6 C₃₅H₃₆F₂O₆S₂ 

Relevant articles and documents

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

ANTI-CD40 ANTIBODY DRUG CONJUGATES

Provided herein are anti-CD40 antibody drug conjugates comprising a radical of Formula (I), wherein R1, R2, and R3 are as defined herein. Further provided are anti-CD40 antibody drug conjugates of Formula (II), wherein Z, R, AA1, AA2, AA3, m, p, q, n, w, R1, R2, and R3 are as defined herein. Further provided are pharmaceutical compositions and kits thereof, and methods of using same.

Kilogram-scale synthesis of an inhaled corticosteroid

The development and implementation of a safe and scalable process for the manufacture of corticosteroid PF-4714224 (1) is described. Initial routes used to synthesise analogues from this series directly from fluocinolone acetonide (2) were unsuitable for large-scale use. Key aspects of the route are the efficient and simple method for the preparation of the steroid tetraol (6), acetal formation by reaction of the tetraol with a bisulphite adduct (12), and isolation of the product by sequential recrystallisations.